• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Revvity Inc.

    3/16/26 8:06:48 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    DEFA14A 1 d54937ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒       Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Revvity, Inc.

    (Name of Registrant as Specified in its Charter)

    Not applicable.

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒   No fee required.
    ☐   Fee paid previously with preliminary materials.
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
     
     


                    
                         
       

     

    Your Vote Counts!

          

           LOGO

     

    REVVITY, INC.

     

    77 4TH AVENUE

    WALTHAM, MA 02451

     

     

    REVVITY, INC.

     

    2026 Annual Meeting

    Vote by April 27, 2026 11:59 PM ET. For shares held in a

    Plan, vote by April 23, 2026 11:59 PM ET.

     

         
       
      LOGO       
       
       
         
         

     

         
     
     
         
     
         

    V85357-P45261-Z91972

                  
               

    You invested in REVVITY, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on April 28, 2026.

    Get informed before you vote

    View the Notice and Proxy Statement and Annual Report OR you can receive a free paper or email copy of the material(s) by requesting prior to April 14, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

    LOGO

     

     

    *Please check the meeting materials for any special requirements for meeting attendance.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

     

     Voting Items

     

     

    Board

    Recommends

     

     

    1.

     

    To elect ten nominees for director for terms of one year each:

     

    Nominees:

     

         
     

    1a.

      Peter Barrett, PhD   LOGO   For
     

    1b.

      Samuel R. Chapin   LOGO   For
     

    1c.

      Michael A. Klobuchar   LOGO   For
     

    1d.

      Michelle McMurry-Heath, MD, PhD   LOGO   For
     

    1e.

      Alexis P. Michas   LOGO   For
     

    1f.

      Prahlad R. Singh, PhD   LOGO   For
     

    1g.

      Sophie V. Vandebroek, PhD   LOGO   For
     

    1h.

      Michel Vounatsos   LOGO   For
     

    1i.

      Frank Witney, PhD   LOGO   For
     

    1j.

      Pascale Witz   LOGO   For
     

    2.

      To ratify the selection of Deloitte & Touche LLP as Revvity’s independent registered public accounting firm for the current fiscal year.   LOGO   For
     

    3.

      To approve, by non-binding advisory vote, our executive compensation.   LOGO   For
     

    4.

      To approve an amendment to Revvity’s Amended and Restated By-Laws to Allow Shareholders Owning 25% of Our Stock to Call a Special Meeting.   LOGO   For
     

    5.

      To approve the shareholder proposal regarding Executives to Retain Significant Stock.   LOGO   Against

    NOTE: The proxies are authorized to vote, in their discretion, upon such other business as may properly come before the meeting or any adjournment or postponement thereof.

       

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V85358-P45261-Z91972           

    Get the next $RVTY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    6/2/2026Peer Perform
    Wolfe Research
    4/14/2026$95.00Overweight → Equal Weight
    Barclays
    12/15/2025$110.00Buy → Neutral
    BofA Securities
    12/9/2025$105.00Neutral
    Goldman
    10/16/2025Neutral
    Guggenheim
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity Announces Financial Results for the First Quarter of 2026

    Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth GAAP EPS from continuing operations of $0.37; adjusted EPS from continuing operations of $1.06; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 Announces intention to divest China Immunodiagnostics business Updates full year 2026 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the

    5/5/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screeni

    4/30/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity to Present at Upcoming Investor Conferences

    Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 9:20 a.m. PT - Steve Willoughby, senior vice president, investor relations, ESG, risk Goldman Sachs 47th Annual Global Healthcare Conference Tuesday, June 9, 2026 8:40 a.m. ET - Prahlad Singh, president and chief executive officer Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and w

    4/16/26 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Revvity

    Wolfe Research resumed coverage of Revvity with a rating of Peer Perform

    6/2/26 8:37:34 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity downgraded by Barclays with a new price target

    Barclays downgraded Revvity from Overweight to Equal Weight and set a new price target of $95.00

    4/14/26 8:17:03 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity downgraded by BofA Securities with a new price target

    BofA Securities downgraded Revvity from Buy to Neutral and set a new price target of $110.00

    12/15/25 9:57:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    SEC Filings

    View All

    SEC Form SD filed by Revvity Inc.

    SD - REVVITY, INC. (0000031791) (Filer)

    6/1/26 8:00:12 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Revvity Inc.

    10-Q - REVVITY, INC. (0000031791) (Filer)

    5/12/26 4:07:05 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    5/5/26 6:37:43 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    5/11/26 4:05:14 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    5/11/26 4:05:15 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    5/11/26 4:05:17 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Financial Results for the First Quarter of 2026

    Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic growth; 6% pro forma organic growth GAAP EPS from continuing operations of $0.37; adjusted EPS from continuing operations of $1.06; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 Announces intention to divest China Immunodiagnostics business Updates full year 2026 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the

    5/5/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screeni

    4/30/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity to Hold Earnings Call on Tuesday, May 5, 2026

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows

    4/10/26 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials